Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

COMPLETED

NCT06071143

PHASE1

Safety and Efficacy of KDSTEM Inj. in Patients With Chronic Kidney Disease

Sponsor: EHL Bio Co., Ltd.

View on ClinicalTrials.gov

Summary

A Single arm, Open-labelled, Dose-escalation, Single-center, Phase 1 Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Autologous Urine-derived Stem Cells, 『KDSTEM Inj.』, in Patients with Chronic Kidney Disease. The aim of this study is to evaluate the safety and preliminary efficacy of KDSTEM Inj. in the treatment in Patients with Chronic Kidney Disease.

Official title: A Single Arm, Open-labelled, Dose-escalation, Single-center, Phase 1 Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Autologous Urine-derived Stem Cells, 『KDSTEM Inj.』, in Patients With Chronic Kidney Disease

Key Details

Gender

All

Age Range

19 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

Start Date

2024-02-29

Completion Date

2026-03-09

Last Updated

2026-06-17

Healthy Volunteers

Conditions

Chronic Kidney Diseases

Interventions

BIOLOGICAL

KDSTEM Inj.

1. Low dose: The following study drugs are pre-mixed with 90mL of 0.9% normal saline and injected intravenously three times over the duration of the study. (Treatment group: KDSTEM Inj. 1.0x10\^8 cells/10mL/2 syringes) 2. High dose: The following study drugs are pre-mixed with 70mL of 0.9% normal saline and injected intravenously three times over the duration of the study. (Treatment group: KDSTEM Inj. 3.0x10\^8 cells/30mL/6 syringes)

Inclusion Criteria: 1. Male or female aged between 19 and 80 at the time of signing the agreement 2. Chronic kidney disease patients with an eGFR of 20 to 59 ml/min/1.73m² by MDRD at the screening and baseline 3. Male or female of childbearing age agreed to use accurate birth control method during this clinical trial 4. Subjects voluntarily signed an agreement in writing for this clinical trial Exclusion Criteria: 1. Subjects who meet any of the following conditions at the screening visit 1. Systemic infection 2. HIV, HBV, HCV, Syphilis (+) 3. Blood pressure higher than 190mmHg of SBP or 110mmHg of DBP 4. AST or ALT higher than 3 times the upper limit of normal values 2. Subjects who received hemodialysis within 12 weeks prior to the screening or will be receive hemodialysis during this clinical trial 3. Subjects who received kidney transplantation or will be receive kidney transplantation during this clinical trial 4. Subjects diagnosed with the following diseases 1. Solid Tumors or Hematologic Malignancies within 5 years prior to the screening 2. Cognitive disorder, Alzheimer's disease or mental illness be clinically significant. 3. Alcohol or drug abuse 4. Severe Respiratory disease (Chronic Obstructive Pulmonary Disease, asthma, pneumonia, pulmonary embolism and pneumothorax, etc.) 5. Stroke 6. Heart related diseases (within 3 months prior to the screening severe cardiovascular conditions (angina Pectoris, myocardial infarction, unstable arrhythmia, heart failure, etc.) 5. Subjects who received cell therapy or another clinical trial product/device within 4 weeks prior to the screening 6. Subjects who were hypersensitivity reaction pertaining to penicillin, streptomycin, and amphotericin B 7. Subjects, as determined by an investigator, receiving treatment anticipated to affect the results of the clinical trials 8. Subjects being pregnant, providing breast milk, resulted in positive pregnancy test at screening or planning for pregnancy during this clinical trial 9. etc. Subjects determined unsuitable for this clinical trial by the investigator

Locations (1)

Chungnam National University Hospital

Daejeon, Chungcheongnam-do, South Korea